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Abstract
Purpose and M ethod. Hyper-fractionated radiotherapy for treatment of soft tissue sarcomas is designed to deliver a higher
total dose of radiation without an increase in late normal tissue damage. In a previous study at the Royal Marsden Hospital,
a total dose of 75 Gy using twice daily 1.25 Gy fractions resulted in a higher incidence of late damage than conventional
radiotherapy using 2 Gy daily fractions treating to a total of 60 Gy. The current trial therefore used a lower dose per fraction
of 1.2 Gy and lower total dose of 72 Gy, with 60 fractions given over a period of 6 weeks.
Subjects. A total of 37 patients (22 males and 15 females) with a median age of 56 years (range 19±88 years) were treated.
Results. Of eight patients treated pre-operatively, six showed a partial response and in two the tumour was static. The
maximum acute toxicities were grade 1 in eight, grade 2 in 14 and grade 3 in 15 patients. Late toxicities of the skin were
graded 1 in 10 and grade 2 in nine patients. Five patients complained of pain in the irradiated bone and soft tissues, which
was of moderate severity (grade 2). Stiffness was graded 2 in three patients and severe (grade 3) in one. Three patients had
moderate and one patient had severe lymphoedema following treatment. The 5-year recurrence-free survival probability of
patients treated radically was 76%. Following excision of local recurrences the study group had a disease-free survival prob-
ability of 86% at 5 years.
Discussion. The regime is well tolerated with comparable local control and late complication rates to standard daily frac-
tionated therapy.The potential bene®t of this regime needs to be de®ned in a prospective randomized trial.
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Introduction
Radiotherapy is an essential component of treatment
for all soft tissue sarcomas (STS) except those which
have been w idely excised or are of low grade.
Conservative surgery and post-operative radiotherapy
is the preferred procedure for limb and limb-g irdle
sarcomas, with 5-year local control rates of 80±90%
repor ted in diffe rent ser ies.1±4 Pre-operative
rad iotherapy may be used (w ith or w ithout
chemotherapy) in tumours not initially amenable to
limb conserving surgery and around a 30% improve-
ment in the rate of limb conservation has been
reported.5±7
Despite best efforts at conservative surgery and
conventional radiotherapy, most studies report local
recurrence rates of up to 20% at 5 years; late local
failure can continue to occur beyond that period.1,2
Tum ours of h igher grade and larger size are
particularly at risk of local failure.2,8,9 Local recur-
rence is observed in about one ®fth of patients with
metastases,2 although it is uncertain whether the risk
of distant metastases is increased following local recur-
rence.2,9 Around 60% of local recurrences can be
controlled with further surgery but amputation may
be necessary.2,5 Studies aimed at further improving
local control of extremity STS are hence of paramount
importance.
It appears that conventional radiotherapy has
reached the limit of its performance and it is impera-
tive that newer modalities/techniques be tested in an
attempt to improve results. Conservative surgery and
brachytherapy is reported successfully to control
locally advanced sarcomas of the limb with good
preservation of function.10 Better target precision and
tumour oxygenation are postulated advantages with
this approach but no signi®cant improvement in
overall results has been observed with brachytherapy
over conventional external beam radiotherapy.10,11
Improved results are reported with the addition of
infusional chemotherapy to radiotherapy in the
pre-operative setting, although at the expense of
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additional toxicity.12±14The initial promise of higher
relative biological effectiveness (RBE) with neutron
therapy in the treatment of these tumours has also
been offset by a decreased therapeutic ratio through
increased late damage.15±17
The possible bene®t of radiotherapy dose escala-
tion in the treatment of STS has not been
prospectively tested. Most radiotherapy schedules
limit the total dose of post-operative radiotherapy to
60±66 Gy in view of the unacceptably high incidence
of late complications with doses above this level. It
was in this setting that altered radiotherapy fractiona-
tion was evaluated in the post-operative treatment of
extremity STS.
The technique of hyper-fractionated radiotherapy
can be used to deliver a higher total dose of radiation
without an increase in late normal tissue damage.18
This approach is proven to be of bene®t in primary
tumours arising in the head and neck, bladder, lung
and in gliomas19,20 but there are few reports on its
efficacy in the treatment of STS. Trials of combined
chemotherapy and hyper-fractionated radiotherapy
in paediatric Ewing’s and rhabdomyosarcoma have
shown promising results21,22 and radiotherapy using
multip le daily fract ions was effe ctive in the
pre-operative setting in combination with radiosensi-
tizing agents.23,24These observations formed the basis
of a pilot study of hyper-fractionated radiotherapy in
the treatment of extremity STS at the Royal Marsden
Hospital.
The ®rst study of hyper-fractionation was designed
to determine the feasibility of irradiating large volumes
to a dose of 75 Gy using twice daily 1.25 Gy frac-
tions with a minimum interval of 6 hours between
fractions.25 Assuming on a/b value of 1.36 for late
responding tissues, the expected late effects with
hyper-fractionated regime were equal to conventional
irradiation using 2 Gy fractions and a total of 60 Gy.
However, it appeared that the late damage caused by
this dose greater than with conventional irradiation,
suggesting higher a/b values for late-responding
tissues.
In order to reduce the incidence and severity of
late complications, we designed the current trial of
hyper-fractionated radiotherapy in extremity STS,
assuming a a/b of 3 for late reaction. By using a lower
dose per fraction of 1.2 Gy and lower total dose of
72 Gy, with 60 fractions being given over a period of
6 weeks, it was expected that the late toxicity would
be equivalent to conventional fractionation. Assuming
an a/b of 10 for tumour, there would be a 11%
increase in the effective dose for tumour control.
Materials and methods
This study was conducted on patients with STS of
the extremity referred to the Sarcoma Unit of the
Royal Marsden Hospital between 1990 and 1995. All
patients were initially assessed by the multidiscipli-
nary team comprising surgeon, radiotherapist and
medical oncologist. Initial investigations included
computed tomography/magnetic resonance imaging
(CT/MRI) scans of the primary site and CT scan of
the chest. Patients referred with no histolog ical
con®rmation of diagnosis underwent tru-cut biopsy
of tumour. All histology specimens were reviewed by
the same pathologist and graded as high, intermediate
or low.
Surgical excision of the tumour was the preferred
mode of treatment whenever possible and patients
who achieved wide excision of a low grade tumour
were not offered post-operative radiotherapy. All
patients with intermediate or high grade tumours
and those in whom tumour was not excised with
wide margins, received post-operative radiotherapy.
This included patients who had `intra-capsular’ or
`m arginal’ resection of tumours by the Enneking’s
classi®cation.6 Pre-operative radiotherapy was given
to patients whose tumours were not initially amenable
to limb-conserving surgery. Palliative radiotherapy was
given for patients with poor performance status or
documented metastatic disease. No patient received
chemotherapy as part of their primary treatment.
A l l p atien ts requ ir ing rad iotherap y were
cons idered fo r treatm ent us ing the hyper-
fractionated protocol. Presence of bowel or neural
tissue in the target volume was the only criterion
for inelig ibility, as the study design did not consider
the a/b ratios and sensitivities of these structures
which are different to soft-tissue. During this time
period, the large majority of patients were treated
conventionally. Only those who were able to attend
for twice daily radiotherapy could be included in
the study, with most being admitted to the ward.
Written informed consent was mandatory.
Patients were immobilized using a perspex cast
and treatment was planned using a CT scan, for
5/6 M V photons in two phases. Phase I volume
included the whole muscle compartment of the limb,
usually with opposing ®elds, angled if necessary, with
or without compensators. For phase II a much smaller
volume encompassing the initial extent of the primary
tumour with a 2 cm margin was used. Care was taken
to leave a corridor of normal tissue un-irradiated in
all patients and to spare the palm, sole, heel, Achilles
tendon, toes and joints whenever possible.26±28 The
pr inciples and techniques of three-dimensional
conformal radiotherapy have been described previ-
ously.29
A phase I dose of 60 Gy followed by a phase II
dose of 12 Gy in 1.2 Gy fractions treating twice a day
was given in 60 fractions over 6 weeks post-operatively.
Alternatively, pre-operative radiotherapy was given
to the phase I volume to 60 Gy over 5 weeks following
which patients were considered for surgery; tumours
which were still not amenable to limb-conserving
surgery were treated further using radiotherapy to a
phase II volume, to a total dose of 72 Gy. Palliative
irradiation was also given to a total dose of 72 Gy in
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two phases. There was always a minimum gap of 6 h
between the two daily fractions.
Patients were m onitored weekly dur ing
radiotherapy: skin erythema, desquamation, oedema
and ulceration were recorded. Toxicity was graded
according to the RTOG radiation morbidity scoring
criteria (Table 1).
Tumour response was assessed 4 weeks after the
end of phase I treatm ent in patients treated
pre-operatively. Tumours with less than 50% reduc-
tion in the product of two perpendicular dimensions
were assessed as having `static disease’. A reduction
in dimensions of 50% or more but short of complete
response was designated a `partial response’. Patients
with `static disease’ were suitable for surgery if the
tumour had become technically operable.
Patients were reviewed at 3-m onthly intervals
dur ing the ®rst 2 years and at longer intervals
thereafter, for evaluating disease status and scoring
late toxicity. RTOG/EORTC late radiation morbidity
scoring scheme was used to study the late effects on
skin, sub-cutaneous tissue, bone and joint; the NCIC
late limb oedema scale was used to score post-
treatment oedema (Table 2). Follow-up CT/MRI
scans of the limb and chest were performed whenever
clinically indicated.
Recurrence-free survival was calculated using the
Kaplan±Meier product limit method. Prognostic vari-
ables for radiation reactions were studied using the
Chi-squared test.
Results
Patient characteristics (Table 3)
Thirty-seven patients underwent treatment using the
hyperfractionated regime. There were 22 males and
15 females with a median age of 56 years (range
19±88 years). Thigh was the commonest site of
presentation, in 15 patients. The other common sites
of tumour were lower leg (n=10) upper arm, and foot
(n=3 each). Leiomyosarcoma (n=14) and malignant
®brous histiocytoma (n=12) were the most frequent
histological subtypes; in two patients the type was not
speci®ed (NOS). In 10 patients the tumour was of
intermediate grade and in 27 patients high grade.
Twenty-nine patients were treated post-operatively
and eight pre-operatively. Post-operative radiotherapy
was given for high grade tumours in 23 patients and
for close margins of excision in six patients.
Thirty patients were treated with radical intent: 27
post-operatively and three pre-operatively. Seven
patients were treated with palliative intent because of
documented metastatic disease but to the same dose.
This included ®ve pre-operative and two post-
operative radiotherapy.
Tumour response and local control (Table 4)
Of the eight patients treated with pre-operative
radiotherapy, six patients showed partial response with
more than 50% reduction in tumor size and in two
Table 1. RTOG acute radiation morbidity scoring criteria
0 1 2 3 4
No change Erythema/epilation/dry
desquamation
Tender or bright
erythema/patchy
moist desquamation/
moderate oedema
Con¯uent moist
desquamation/pitting
oedema
Ulceration/haemorrhage/
necrosis
Table 2. RTOG late radiation morbidity scoring criteria and NCIC late limb oedema scale
0 1 2 3 4
Skin None Slight
atrophy/
pigmentation/some
hair loss
Patchy
atrophy/moderate
telangiectasia/total
hair loss
Marked
atrophy/gross
telangiectasia
Ulceration
Subcutaneous
tissue
None Slight
induration/Loss of
sub-cutaneous fat
Moderate
®brosis/slight ®eld
contracture
contracture/<10%
linear reduction
Severe
induration/®eld
contracture/>10%
linear measurement
Necrosis
Bone None Asymptomatic/no
growth
retardation/reduced
bone density
Moderate
pain/growth
retardation/irregular
bone sclerosis
Severe pain/complete
arrest of bone
growth/dense bone
sclerosis
Necrosis/spontaneous
fracture
Joint None Mild joint
stiffness/limitation of
movement
Moderate
stiffness/joint
pain/limitation of
movement
Severe joint
stiffness/pain/severe
limitation of
movement
Necrosis/complete
®xation
Oedema None Slight but de®nite Moderate Considerable
swelling
Skin shiny and tight
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the tumour was static with less than 50% reduction.
All three patients treated with radical intent had partial
response and underwent limb-conserving surgery.
Surgery was performed after 60 Gy in one patient
and after 72 Gy in two patients. All three patients
died of distant metastases. One patient also had
evidence of local recurrence at 18 months after
surgery. Of the ®ve patients treated with palliative
intent, three showed partial response to irradiation
and the disease was static in the remaining two. One
patient with static disease underwent limb amputa-
tion. All ®ve patients died of distant metastases.
Twenty-n ine patients received post-operative
rad iotherapy. Two patients who received post-
operative radiotherapy with palliative intent died of
metastatic disease, with no evidence of local recur-
rence. Five of 27 patients treated with radical post-
operative radiotherapy developed local recurrence of
tumour.Three of these patients had excision of recur-
rence and are alive and free of disease. The other two
patients had metastatic disease such that no further
surgery was offered. Both these patients died of
metastatic disease before the recurrent tum our
became symptomatic. Nine patients died of metastatic
disease without evidence of local recurrence.
Of 30 patients treated radically (27 with post-
operative and three with pre-operative radiotherapy)
there were a total of six local failures (®ve and one,
respectively). Sixteen patients developed distant
metastases of whom three also failed locally. The
mean time to develop metastases was 23 months
(range 1±92 months).
All seven patients treated palliatively (two with post-
operative and ®ve with pre-operative radiotherapy)
died of distant metastases. Four patients treated with
pre-operative radiotherapy showed no evidence of
tumour progression at the time of death. One patient
with `static’ response to pre-operative irradiation had
subsequent tum our progression of disease and
underwent amputation of the limb.
Thirty-®ve patients completed the planned course
of treatment without interruption. Treatment was
stopped in two patients treated post-operatively at
58.8 and 64.8 Gy due to break-down of the surgical
¯ap.
Patients in this study had a median follow up of 44
months (range 2±114). The 5-year recurrence-free
survival probability in patients treated with radical
intent using pre- or post-operative hyperfractionated
radiotherapy, was 76% . The 5-year disease-free
survival after surgical salvage was 86%.
Early reactions
The maximum acute toxicity was only grade 1 in
eight patients and 14 patients had grade 2 toxicity.
Grade 3 toxicity was recorded in 15 patients, but
none developed ulceration or necrosis (grade 4 toxic-
ity). Nine patients had breakdown of their grafts while
on radiotherapy not graded as grade 4 radiation
toxicity. Breakdown of surgical scars/grafts could not
be entirely attributed to radiotherapy treatment, and
graft breakdown occurred before the onset of grade 2
or 3 toxicity in six patients. Graft breakdown was
complicated by infection in three patients and, in the
other six, the breakdown was minor, healing with
conservative management.
Table 4. Hyper-fractionated radiotherapy in STS: treatment outcome
Treatment Intent
Complete
response
Partial
response Static
Local
failure
Distant
failure Both
Disease-
free
Post-operative
(n=29)
Radical
(n=27)
Ð Ð Ð 3* 9 2 16*
Palliative
(n=2)
Ð Ð Ð Ð 2 0 0
Pre-operative
(n=8)
Radical
(n=3)
Ð 3** Ð Ð 2 1 0
Palliative
(n=5)
Ð 3 2 Ð Ð 5 0
*All three patients underwent excision of local recurrence and are alive disease-free.
**Three patients underwent complete surgery after pre-operative radiotherapy.
Table 3. Patient characteristics
Characteristics Post-operative Pre-operative
Number 29 8
Gender
Male 17 5
Female 12 3
Mean age (years) 56 56
Mean tumour size (cm) 9.1 9.5
Site
Thigh 13 2
Lower leg 6 4
Other 10 2
Histology
LMS
1
12 2
MFH
2
8 4
Others 9 2
Grade
Intermediate 6 4
High 23 4
1, Leiomyosarcoma; 2, malignant ®brous histiocytoma.
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Figure 1 shows the time in weeks at which toxici-
ties developed. Acute reactions generally developed
during the second week of treatment and more than
60% of grade 1 toxicities occurred by the end of
week 3. Grade 2 toxicity peaked around the ®fth
week of radiotherapy and continued to develop
throughout the duration of treatment. Progression to
grade 3 toxicity was common around week 6. Acute
radiation reactions were the same within the phase I
and II radiation ®elds and there was no increase in
incidence or severity of acute toxicity within the phase
II volume.
Late reactions
Late radiation morbidity was assessed in 32 patients.
Assessment was not possible in three patients as they
died of metastatic disease before the development of
late changes. One patient underwent amputation
fo llow ing par tia l response to pre-operative
radiotherapy and one patient was lost to follow-up.
Late morbidity was most commonly observed in
the skin and sub-cutaneous tissues. Ten patients had
only grade 1 morbidity of the skin with pigmentation
and nine patients grade 2 morbidity with moderate
telangectasia. In the sub-cutaneous tissue, induration
was recorded as slight (grade 1) in 11, moderate
(grade 2) in nine and severe (grade 3) in one patients.
Five patients complained of pain in the irradiated
bone or soft tissues, which was of moderate severity
(grade 2). Five patients had mild (grade 1) stiffness
of the irradiated joint. Stiffness was graded 2 in three
patients and severe (grade 3) in one. Lymphoedema
was slight (grade 1) in 13 patients, moderate (grade
2) in three and considerable (grade 3) in one.
Incidence of grade 2 or 3 late radiation morbidity
of the sub-cutaneous tissue, bone or joint were higher
in patients treated with phase II ®eld areas greater
than 250 cm2, although this was not statistically
signi®cant (g iven the small num ber of events
recorded).
Figures 2-4 show an ulcerated STS treated with
wide excision and hyperfractionated radiotherapy,
with excellent results.
Discussion
In the previous study of hyper-fractionated
radiotherapy at the Royal Marsden Hospital, a total
dose of 75 Gy in twice daily 1.25 Gy fractions was
tested. Assuming an a/b ratio for late damage of
1.36, it was expected that this regime would give
equivalent late toxicity compared to 60 Gy in 30 frac-
tions.26 The late effects from that study were greater
than with conventional frac tionation and in our
current study an 11% increase in the therapeutic
ratio was expected for the same late effects, assuming
a higher a/b ratio of 3 for late-responding tissues.
Comparison of results with that of our previous
study shows a slightly reduced incidence in grade 2±4
acute radiation morbidity (43 vs 48%).The new group
of patients have a minimum follow-up period of 33
months, with a median of 44 months, enabling scoring
of most late radiation reactions. A shorter median
follow-up period in the previous study would suggest
that the actual incidence of late toxicity could be
even higher than reported. The incidence of grade 2
or 3 induration is 27% in this study contrasted with
53% in the previous study. An overall local control
probability of 86% at 5 years in this study compares
Figure 1. Graph showing the week of onset of acute radiation toxicity.
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favo urably w ith results using conven tional
rad iotherapy.1,2,30 This sugges ts that hyper-
fractionated radiotherapy using twice daily 1.2 Gy
fractions is well tolerated with good local control
rates and no increase in the incidence of late toxicity.
There is some evidence to suggest that soft tissue
sa rcomas show a dose response to irradiation,
although this has not been proven. In a group of
patients with advanced STS treated with radiotherapy
alone,Tepper reported better local control in patients
receiving 64 Gy or more.9 Similar results were also
reported by Slater et al. with better local control of
tumour in patients receiving more that 65 Gy.31 In a
retrospective analysis by Tanabe and colleagues, a
higher rate of local recurrence was seen in patients
treated with pre-operative radiotherapy.32 Levine et
al. reported higher local recurrence rates in patients
treated with a pre-operative dose of 25 Gy in 10
fractions with chemotherapy rates compared to those
who received additional post-operative boost
radiotherapy.33 These data suggest that a dose
response does exist in the radiotherapy treatment of
ST S. In our exper ience, patients treated w ith
pre-operative radiotherapy to doses over 60 Gy had
up to 80% response rates.34
The incidence of late morbidity is greater with use
of a higher total dose of radiotherapy and higher dose
per fraction. In the series by Slater, major complica-
tions were increased in patients treated to 70 Gy or
more.31 In a previous study performed at our centre,
the degree of ®brosis was related to total dose of
radiotherapy in patients treated for STS of the extrem-
ity.35 Selch reported a signi®cantly higher rate of
toxicity in patients treated pre-operatively with high
Figure 2. Photog raph of an ulcerated soft tissue sarcoma in the upper outer aspect of the lower leg in an 88-year-old woman.
Figure 3. Photog raph of the leg in Fig. 2 following wide excision of a 103 10 cm, g rade 3 leiomyosarcoma and repair of the defect.
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dose per fraction radiotherapy and concurrent
chemotherapy.36 Hence a total dose of 60±66 Gy in
2 Gy fractions is seldom exceeded in the treatment of
these tumours, especially as the volumes treated are
large and inevitably include a substantial amount of
adjacent normal tissue.
Hyper-fractionated radiotherapy exploits the differ-
ences in fractionation response between tumour and
normal tissue, by virtue of their different a/b ratios.
Where the tumour has an a/b ratio exceeding that of
late responding tissue, this technique could be used
to deliver a higher total dose of radiation without an
increase in late normal tissue damage.18 Although
studies on experimental tumours suggests a low a/b
ratio in sarcomas37 hyper-fractionation has not been
extensively tested in the clinical setting.
There are only few published trials of hyper-
fractionated radiotherapy in soft tissue sarcomas.
Trials of com bined chem otherapy and hyper-
fractionated radiotherapy in paediatric Ewing’s and
rhabdomyosarcom a have shown prom is ing
results.38,39 In a study by Mandell et al., alternating
chemotherapy and hyper-fractionated radiotherapy
were used in gross residual or metastatic paediatric
rhabdomyosarcoma. Patients were treated to a total
dose of 54 Gy in 1.5 Gy fractions, treating twice a
day with lesser acute toxicity and fewer treatment
interruptions com pared w ith concurrent
chemotherapy and conventional radiotherapy.38,40
Dunst et al. reported the use of hyper-fractionated
radiotherapy in combination with chemotherapy in
the treatment of paediatric Ewing’s sarcoma.39
Willet et al. compared conventional radiotherapy
to twice daily hyperfractionated radiotherapy (1.8±
2 Gy fractions separated by 4 h) in STS of borderline
resectability. Signi®cantly better histological response
was noted in the group treated using the hyper-
fractionated regime. This suggested that hyperfrac-
tionated radiotherapy may be usefu l in the
conservative surgical excision of STS of border-line
resectability.23 Hyper-fractionated radiotherapy has
been used with radio-sensitizing agents in the treat-
ment of advanced STS. In a group of 36 patients
with unresectable STS at different sites treated with
hyper-fractionated radiotherapy in 1.5 Gy twice daily
fractions to a dose of 70±75 Gy in combination with
Iododeoxyuridine, Goffman et al. reported 60% local
control, with moderate toxicity.41
It is important to test the efficacy of hyper-
fract ionated rad iotherapy prospectively w ith
conventional fractionation. Accurate comparison of
late tox icity between conventional and hyper-
fractionated regimes is essential possibly to escalate
the dose of radiation in the hyper-fractionated arm.
Historical controls are of limited use in this regard
and radiobiological predictions require clinical valida-
tion.
We propose to conduct a multi-arm trial, comparing
hyper-fractionated with conventional radiotherapy in
the post-operative treatment of STS. Patients with
macroscopic residue following initial surgery are rand-
omized for re-excision, followed by conventional or
hyper-fractionated radiotherapy. Patien ts w ith
complete excision or microscopic residual disease are
randomized directly into the radiotherapy arms. This
trial would help to assess the role of hyper-fractionated
radiotherapy and surgical re-excision in local control
of STS.
Conclusion
It is feasib le to del ive r hyper-f ra ct ionated
radiotherapy to a total dose of 72 Gy using twice
daily 1.2 Gy fractions over 6 weeks in the treatment
of STS of the extremity. The regime is well toler-
ated with comparable local control rates and late
morbidity compared with standard irradiation. The
Figure 4. Seven years after surger y and post-operative hyper-fractionated irradiation, the patient is free of disease. She enjoys good
limb function despite mild joint stiffness.
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advan tage o f th is reg im e over conven tiona l
radiotherapy needs to be con®rmed by a prospec-
tive randomized trial.
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